Scientists are developing artificial intelligence models that could simulate how human cells respond to drugs and genetic changes, potentially allowing researchers to test some ideas computationally before moving them into expensive laboratory experiments.
GenBio AI is among the companies pursuing the technology. The Palo Alto-based startup developing what it calls an AI-driven digital organism that connects biological information across multiple scales. The aim is to model interactions spanning molecules, proteins, cells and eventually broader biological outcomes.
